N Gachard
Overview
Explore the profile of N Gachard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
250
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abbaci A, Talbot H, Saada S, Gachard N, Abraham J, Jaccard A, et al.
Oncogene
. 2017 Oct;
37(6):756-767.
PMID: 29059151
B-cell chronic lymphocytic leukemia (B-CLL) cells are resistant to apoptosis, and consequently accumulate to the detriment of normal B cells and patient immunity. Because current therapies fail to eradicate these...
2.
Troadec E, Dobbelstein S, Bertrand P, Faumont N, Trimoreau F, Touati M, et al.
Leukemia
. 2016 Nov;
31(2):514-517.
PMID: 27795560
No abstract available.
3.
Rizzo D, Chauzeix J, Trimoreau F, Woillard J, Genevieve F, Bouvier A, et al.
Leukemia
. 2014 Jun;
29(2):337-45.
PMID: 24943833
We examined the significance of IgM peaks in chronic lymphocytic leukemia (CLL), including its association with newly reported MYD88, BIRC3, NOTCH1 and SF3B1 mutations. A total of 27, 25, 41...
4.
Chanut A, Duguet F, Marfak A, David A, Petit B, Parrens M, et al.
Leukemia
. 2013 Sep;
28(4):871-9.
PMID: 24056880
In this study, we determined the respective roles of RelA and RelB NF-κB subunits in Epstein-Barr virus (EBV)-transformed B cells. Using different EBV-immortalized B-cell models, we showed that only RelA...
5.
Gachard N, Parrens M, Soubeyran I, Petit B, Marfak A, Rizzo D, et al.
Leukemia
. 2012 Sep;
27(1):183-9.
PMID: 22944768
To clarify the relationships between marginal zone lymphomas (MZLs) and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas (WM/LPLs), immunoglobulin heavy chain variable gene (IGHV) features were analyzed and the occurrence of MYD88 L265P mutations...
6.
Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault M, et al.
Leukemia
. 2011 Feb;
25(6):939-44.
PMID: 21331073
A simplified prognostic score is presented based on the multivariate analysis of 138 refractory/relapsed acute myeloid leukaemia (AML) patients (median age 55 years, range: 19-70) receiving a combination of intensive...
7.
Couronne L, Lippert E, Andrieux J, Kosmider O, Radford-Weiss I, Penther D, et al.
Leukemia
. 2009 Aug;
24(1):201-3.
PMID: 19710701
No abstract available.
8.
Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini J, et al.
Ann Oncol
. 2008 Aug;
20(1):110-6.
PMID: 18701429
Background: Extranodal natural killer (NK)/T-cell lymphoma, nasal type, and aggressive NK-cell leukemia are highly aggressive diseases with a poor outcome. Patients And Methods: We report a multicentric French retrospective study...
9.
Parrens M, Gachard N, Petit B, Marfak A, Troadec E, Bouabdhalla K, et al.
Leukemia
. 2008 Feb;
22(8):1621-4.
PMID: 18305562
No abstract available.
10.
Youlyouz-Marfak I, Gachard N, Le Clorennec C, Najjar I, Baran-Marszak F, Reminieras L, et al.
Cell Death Differ
. 2007 Nov;
15(2):376-85.
PMID: 17992189
Chemotherapeutic drugs such as fludarabine*, doxorubicin or cisplatin are very potent activators of the anti-oncogene p53. Convergent studies suggest that p53 and STAT1 (signal transducer and activator of transcription 1)...